MicroRNA-145-loaded poly(lactic-co-glycolic acid) nanoparticles attenuate venous intimal hyperplasia in a rabbit model

Nishio, Hiroomi; Masumoto, Hidetoshi; Sakamoto, Kazuhisa; Yamazaki, Kazuhiro; Ikeda, Tadashi; Minatoya, Kenji

doi:10.1016/j.jtcvs.2018.08.115

Cited by 26 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, these delivery systems have been tested with great results for pulmonary administration of different drugs (Feng et al 2014;Gaspar et al 2019;Takami and Murakami 2011). Furthermore, therapeutic gene delivery based on these systems has been explored especially loading pDNA, mRNA, siRNA and microRNA (Gomes dos Reis et al 2019;Matta and Maalouf 2019;Nishio et al 2018;Terry et al 2019;Xu et al 2018;Zhao et al 2018).…”

Section: Introductionmentioning

confidence: 99%

Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles

Elmowafy

Tiboni

Soliman

2019

J. Pharm. Investig.

416

208

View full text Add to dashboard Cite

Background Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) are among the well-documented FDAapproved polymers used for the preparation of safe and effective vaccine, drug and gene delivery systems using well-described reproducible methods of fabrication. Various nano and microparticulates are fabricated using these polymers. Their successful performance relies on PLA and PLGA biocompatibility and degradability characteristics. Area covered This review provides an overview of the biocompatibility and biodegradation of PLA, PLGA and their copolymers, with a special emphasis on tissue responses for these polymers as well as their degradation pathways and drug release models. Moreover, the potential of PLA and PLGA based nano and microparticulates in various advanced biomedical applications is highlighted. Expert opinion PLA and PLGA based delivery systems show promises of releasing different drugs, proteins and nucleic acids in a stable and controlled manner and greatly ameliorating their therapeutic efficacy. In addition, advancement in surface modification and targeting of nanoparticles has extended the scope of their utility.

show abstract

Section: Introductionmentioning

confidence: 99%

Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles

Elmowafy

Tiboni

Soliman

2019

J. Pharm. Investig.

416

208

View full text Add to dashboard Cite

show abstract

“…Circulating miR-145 has been also shown to alter VSMCs' phenotype from a proliferative to a contractile state [23]. MiR-145-mediated VSMCs' phenotypic switch and its mediated impact on neointimal formation have been recently demonstrated in several experimental designs [24,25].…”

Section: Circulating Micrornas and Bicuspid Aortopathymentioning

confidence: 99%

Unravelling the Pathogenetic Mechanisms in Congenital Aortopathies: Need for an Integrative Translational Approach

Girdauskas

Kaemmerer

Kodolitsch

2020

JCM

View full text Add to dashboard Cite

Congenital heart disease (CHD)-associated aortopathy is a very heterogeneous entity with a wide spectrum of clinical presentations. The pathogenesis of aortopathy is still incompletely understood, and, therefore, the best prevention and management strategy is currently unknown. The most common entity of CHD-associated aortopathies is bicuspid aortic valve (BAV)-associated aortic disease (so called bicuspid aortopathy) that is found in 50%–60% of BAV individuals. BAV aortopathy has been reported in association with an increased risk of aortic events, especially aortic dissection and sudden cardiac death. Risk stratification of adverse aortic events is still very rudimentary and considers only the maximal aortic diameter, which makes it unsuitable for an individual risk prediction. This introductory Editorial highlights the unmet clinical need for more integrative and translational research to unravel pathogenetic pathways in the development of CHD-associated aortopathies, integrating recently identified genetic lesions and knowledge on circulating biomarkers and microstructural changes in the diseased aorta.

show abstract

“…These results support further development of MK2i-NPs as a therapy for blocking VSMC phenotype switch and IH associated with cardiovascular procedures. JCI Insight 2021;6 (19):e142339 https://doi.org/10.1172/jci.insight.142339…”

Section: Introductionmentioning

confidence: 99%

Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch

Tierney¹,

Evans²,

Cheung‐Flynn³

et al. 2021

JCI Insight

View full text Add to dashboard Cite

MicroRNA-145-loaded poly(lactic-co-glycolic acid) nanoparticles attenuate venous intimal hyperplasia in a rabbit model

Cited by 26 publications

References 42 publications

Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles

Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles

Unravelling the Pathogenetic Mechanisms in Congenital Aortopathies: Need for an Integrative Translational Approach

Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch

Contact Info

Product

Resources

About